Chemotherapy Induced Peripheral Neuropathy Cipn Epidemiology Forecast

DelveInsight’s ‘Chemotherapy Induced Peripheral Neuropathy (CIPN) - Epidemiology Forecast–2030’ report delivers an in-depth understanding of the CIPN, historical and forecasted epidemiology as well as the CIPN trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017–2030


Chemotherapy Induced Peripheral Neuropathy (CIPN) Disease Understanding

Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent, dose-dependent complication of anticancer drugs, including platinum-containing agents, taxanes, epothilones, vinca alkaloids, and newer agents, such as bortezomib. It not only leads to dose reduction or discontinuation of treatment but also decreases the quality of life of cancer survivors.


CIPN occurs in ~20% of patients given standard doses of chemotherapy and in almost 100% of patients treated with high doses.


CIPN presents clinically as deficits in sensory, motor, and sometimes autonomic function. Sensory disturbances range from a mild tingling sensation to spontaneous burning pain and hypersensitivity to stimuli.


Chemotherapy Induced Peripheral Neuropathy (CIPN) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of CIPN, Severity Specific Incident Population of CIPN, Incident Population of CIPN by Chemotherapeutic Agents, and Incident Population of CIPN by Cancer Type scenario of CIPN in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.


Chemotherapy Induced Peripheral Neuropathy (CIPN) Detailed Epidemiology Segmentation

  • The United States showed the highest incident population of CIPN. As per DelveInsight estimates, the US accounts for approximately 41.11% of total cases, for CIPN, in the 7MM countries. In 2017, the incident population of CIPN in the US was found to be 598,908.
  • In 2017, incident cases of mild, moderate and severe CIPN in the US were 173,683, 305,443, and 119,782 respectively. Assessments as per DelveInsight’s analysts show that the overall incidence of moderate CIPN was maximum, followed by mild and severe, and is subjected to increase rapidly in the coming years.
  • In 2017, the incident population of CIPN in the US by cancer type was accounted for 82,082 for Breast Cancer, 60,620 for colorectal cancer. CIPN in Lung Cancer patients were estimated to be 48,724 in 2017
  • Among the European countries, Germany had the highest incident population of CIPN with 165,095 cases, followed by the United Kingdom which had the incident population of 120,624 in 2017. On the other hand, Spain had the lowest incident population of 73,071 in 2017.
  • As per DelveInsight’s estimates, Japan accounts for approximately 18.11% of the total incident cases in the 7MM. In 2017, the incident population of CIPN in Japan was found to be 263,842.


Scope of the Report

  • The report covers the descriptive overview of CIPN, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report assesses the disease risk and burden of CIPN.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Incident Cases of CIPN, Severity Specific Incident Population of CIPN, Incident Population of CIPN by Chemotherapeutic Agents, and Incident Population of CIPN by Cancer Type.


Report Highlights

  • 11-Year Forecast of CIPN
  • 7MM Coverage
  • Total Incident Cases of CIPN
  • Severity Specific Incident Population of CIPN
  • Incident Population of CIPN by Chemotherapeutic Agents
  • Incident Population of CIPN by Cancer Type


Key Questions Answered

  • What are the disease risk and burden of CIPN?
  • What is the historical CIPN patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of CIPN at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to CIPN?
  • Out of the above-mentioned countries, which country would have the highest incident population of CIPN during the forecast period (2020–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?


Reasons to buy

The Chemotherapy Induced Peripheral Neuropathy (CIPN) report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM CIPN epidemiology forecast.
  • The CIPN epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The CIPN epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2.  Executive Summary of Chemotherapy-Induced Peripheral Neuropathy

2.1. Epidemiology Share (%) Distribution of Chemotherapy-Induced Peripheral Neuropathy in 2017

2.2. Epidemiology Share (%) Distribution of Chemotherapy-Induced Peripheral Neuropathy in 2030

3. Chemotherapy-Induced Peripheral Neuropathy: Disease Background and Overview

3.1. Introduction

3.2.Chemotherapy-Induced Peripheral Neuropathy (CIPN)

3.3.Clinical Features

3.4.Symptoms of CIPN

3.5.Grading of chemotherapy-induced peripheral neuropathy

3.6.Pathophysiology of CIPN

3.7. Chemotherapy-Induced Peripheral Neuropathy: Clinical Presentation

3.8.Genetics of chemotherapy-induced peripheral neuropathy

3.9.Diagnosis of CIPN

3.10.Diagnosis Algorithm

4.Epidemiology and Patient Population

4.1. Key Findings

4.2. Methodology

4.3. Total Incident Population of CIPN in the 7MM

5. Assumptions and Rationale: 7MM

6. Country Wise-Epidemiology of CIPN

6.1. United States

6.1.1. Assumptions and Rationale

6.1.2. Total Incident Population of CIPN in the United States

6.1.3. Severity Specific Incident Population of CIPN in the United States

6.1.4. Incident Population of CIPN by Chemotherapeutic Agents in the United States

6.1.5. Incident Population of CIPN by Cancer Type in the United States

6.2. EU5 countries

6.2.1. EU-5 Assumptions and Rationale

6.2.2. Germany

6.2.2.1. Total Incident Population of CIPN in Germany

6.2.2.2. Severity Specific Incident Population of CIPN in Germany

6.2.2.3. Incident Population of CIPN by Chemotherapeutic Agents in Germany

6.2.2.4. Incident Population of CIPN by Cancer Type in Germany

6.2.3. France

6.2.3.1. Total Incident Population of CIPN in France

6.2.3.2. Severity Specific Incident Population of CIPN in France

6.2.3.3. Incident Population of CIPN by Chemotherapeutic Agents in France

6.2.3.4. Incident Population of CIPN by Cancer Type in France

6.2.4. Italy

6.2.4.1. Total Incident Population of CIPN in Italy

6.2.4.2. Severity Specific Incident Population of CIPN in Italy

6.2.4.3. Incident Population of CIPN by Chemotherapeutic Agents in Italy

6.2.4.4. Incident Population of CIPN by Cancer Type in Italy

6.2.5. Spain

6.2.5.1. Total Incident Population of CIPN in Spain

6.2.5.2. Severity Specific Incident Population of CIPN in Spain

6.2.5.3. Incident Population of CIPN by Chemotherapeutic Agents in Spain

6.2.5.4. Incident Population of CIPN by Cancer Type in Spain

6.2.6. United Kingdom

6.2.6.1. Total Incident Population of CIPN in the UK

6.2.6.2. Severity Specific Incident Population of CIPN in the UK

6.2.6.3. Incident Population of CIPN by Chemotherapeutic Agents in the UK

6.2.6.4. Incident Population of CIPN by Cancer Type in the UK

7.Japan

7.1. Assumptions and Rationale

7.2.Total Incident Population of CIPN in Japan

7.3.Severity Specific Incident Population of CIPN in Japan

7.4.Incident Population of CIPN by Chemotherapeutic Agents in Japan

7.5.Incident Population of CIPN by Cancer Type in Japan

8. Appendix

8.1. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

List of Tables

Table 1 Summary of Chemotherapy-Induced Peripheral Neuropathy, Epidemiology, and Key Events (2017–2030)

Table 2 Common signs and symptoms observed in patients with CIPN

Table 3 Grading scales for chemotherapy-Induced Peripheral Neuropathy

Table 4 Characteristics of the peripheral neurotoxicity caused by the most frequently used antineoplastic agents

Table 5 Core Diagnostic Criteria for Chemotherapy-Induced Peripheral Neuropathy

Table 6 Some of the tools used for assessing CIPN

Table 7 Evaluations that should be performed prior to prescribing an analgesic in elderly patients

Table 8 Brief Tests for the Evaluation of Balance

Table 9 Total Incident Population of CIPN in the 7MM (2017-2030)

Table 10 Total Incident Population of CIPN in the US (2017-2030)

Table 11 Severity Specific Incidence of CIPN in the US (2017-2030)

Table 12 Incident Population of CIPN by Chemotherapeutic Agents in the US (2017-2030)

Table 13 Incident Population of CIPN by Cancer Type in the US (2017-2030)

Table 14 Total Incident Population of CIPN in Germany (2017-2030)

Table 15 Severity Specific Incidence of CIPN in Germany (2017-2030)

Table 16 Incident Population of CIPN by Chemotherapeutic Agents in Germany (2017-2030)

Table 17 Incident Population of CIPN by Cancer Type in Germany (2017-2030)

Table 18 Total Incident Population of CIPN in France (2017-2030)

Table 19 Severity Specific Incidence of CIPN in France (2017-2030)

Table 20 Incident Population of CIPN by Chemotherapeutic Agents in France (2017-2030)

Table 21 Incident Population of CIPN by Cancer Type in France (2017-2030)

Table 22 Total Incident Population of CIPN in Italy (2017-2030)

Table 23 Severity Specific Incidence of CIPN in Italy (2017-2030)

Table 24 Incident Population of CIPN by Chemotherapeutic Agents in Italy (2017-2030)

Table 25 Incident Population of CIPN by Cancer Type in Italy (2017-2030)

Table 26 Total Incident Population of CIPN in Spain (2017-2030)

Table 27 Severity Specific Incidence of CIPN in Spain (2017-2030)

Table 28 Incident Population of CIPN by Chemotherapeutic Agents in Spain (2017-2030)

Table 29 Incident Population of CIPN by Cancer Type in Spain (2017-2030)

Table 30 Total Incident Population of CIPN in the UK (2017-2030)

Table 31 Severity Specific Incidence of CIPN in the UK (2017-2030)

Table 32 Incident Population of CIPN by Chemotherapeutic Agents in the UK (2017-2030)

Table 33 Incident Population of CIPN by Cancer Type in the UK (2017-2030)

Table 34 Total Incident Population of CIPN in (2017-2030)

Table 35 Severity Specific Incidence of CIPN in (2017-2030)

Table 36 Incident Population of CIPN by Chemotherapeutic Agents in (2017-2030)

Table 37 Incident Population of CIPN by Cancer Type in Japan (2017-2030)

List of Figures

Figure 1 Common agents provoking CIPN

Figure 2 Clinical Presentation of CIPN

Figure 3 Algorithm for Nursing Assessment and Management of Chemotherapy-Induced Peripheral Neuropathy

Figure 4 A practical assessment approach for CIPN

Figure 5 Total Incident Population of CIPN in the 7MM (2017-2030)

Figure 6 Global Heat Map of All Cancers

Figure 7 Total Incident Population of CIPN in the US (2017-2030)

Figure 8 Severity Specific Incidence of CIPN in the US (2017-2030)

Figure 9 Incident Population of CIPN by Chemotherapeutic Agents in the US (2017-2030)

Figure 10 Incident Population of CIPN by Cancer Type in the US (2017-2030)

Figure 11 Total Incident Population of CIPN in Germany (2017-2030)

Figure 12 Severity Specific Incidence of CIPN in Germany (2017-2030)

Figure 13 Incident Population of CIPN by Chemotherapeutic Agents in Germany (2017-2030)

Figure 14 Incident Population of CIPN by Cancer Type in Germany (2017-2030)

Figure 15 Total Incident Population of CIPN in France (2017-2030)

Figure 16 Severity Specific Incidence of CIPN in France (2017-2030)

Figure 17 Incident Population of CIPN by Chemotherapeutic Agents in France (2017-2030)

Figure 18 Incident Population of CIPN by Cancer Type in France (2017-2030)

Figure 19 Total Incident Population of CIPN in Italy (2017-2030)

Figure 20 Severity Specific Incidence of CIPN in Italy (2017-2030)

Figure 21 Incident Population of CIPN by Chemotherapeutic Agents in Italy (2017-2030)

Figure 22 Incident Population of CIPN by Cancer Type in Italy (2017-2030)

Figure 23 Total Incident Population of CIPN in Spain (2017-2030)

Figure 24 Severity Specific Incidence of CIPN in Spain (2017-2030)

Figure 25 Incident Population of CIPN by Chemotherapeutic Agents in Spain (2017-2030)

Figure 26 Incident Population of CIPN by Cancer Type in Spain (2017-2030)

Figure 27 Total Incident Population of CIPN in the UK (2017-2030)

Figure 28 Severity Specific Incidence of CIPN in the UK (2017-2030)

Figure 29 Incident Population of CIPN by Chemotherapeutic Agents in the UK (2017-2030)

Figure 30 Incident Population of CIPN by Cancer Type in the UK (2017-2030)

Figure 31 Total Incident Population of CIPN in Japan (2017-2030)

Figure 32 Severity Specific Incidence of CIPN in Japan (2017-2030)

Figure 33 Incident Population of CIPN by Chemotherapeutic Agents in Japan (2017-2030)

Figure 34 Incident Population of CIPN by Cancer Type in Japan (2017-2030)

  • Tags:
  • Chemotherapy Induced Peripheral Neu...
  • Chemotherapy Induced Peripheral Ne...
  • Chemotherapy Induced Peripheral Ne...
  • Chemotherapy Induced Peripheral Ne...
  • Chemotherapy Induced Peripheral Ne...
  • Chemotherapy Induced Peripheral Ne...
  • Chemotherapy Induced Peripheral Ne...
  • Chemotherapy Induced Peripheral Ne...

Forward to Friend

Need A Quote